Wei, X., Du, Y., Lai, Y., Tan, Z., Dai, J., Li, C., Gu, J., Kong, Y., Cui, C., Chi, Z., Lian, B., Tang, B., Wang, X., Li, S., Zhou, L., Guo, J., Liu, J., Mao, L., Si, L. (2026). Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage III acral melanoma: Updated CAP 03-NEO trial results and external control comparison.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.9571